Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Adlyxin
2. Aqve-10010
3. Ave 0010
4. Ave 010
5. Ave-0010
6. Ave-010
7. Ave0010
8. Des-38-proline-exendine-4 (heloderma Suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide
9. Lyxumia
10. Zp 10
11. Zp-10
12. Zp10a Peptide
1. Zp 10
2. Ave0010
3. 320367-13-3
4. Aqve-10010
5. Zp10a Peptide
6. Ave 0010
7. Des-38-proline-exendine-4 (heloderma Suspectum)-(1-39)-peptidylpenta-l-lysyl-l-lysinamide
8. H-his-gly-glu-gly-thr-phe-thr-ser-asp-leu-ser-lys-gln-met-glu-glu-glu-ala-val-arg-leu-phe-ile-glu-trp-leu-lys-asn-gly-gly-pro-ser-ser-gly-ala-pro-pro-ser-lys-lys-lys-lys-lys-lys-nh2
9. Lixisenatide [usan:inn]
10. Lixisenatida
11. Lixisenatidum
12. Unii-74o62bb01u
13. Ave 010
14. Ave-010
15. Zp-10
16. Despro36exendin-4(1-39)-lys6-nh2
17. Chebi:85662
18. 74o62bb01u
19. 367l133
20. H-hgegtftsdlskqmeeeavrlfiewlknggpssgappskkkkkk-nh2
21. H-l-his-gly-l-glu-gly-l-thr-l-phe-l-thr-l-ser-l-asp-l-leu-l-ser-l-lys-l-gln-l-met-l-glu-l-glu-l-glu-l-ala-l-val-l-arg-l-leu-l-phe-l-ile-l-glu-l-trp-l-leu-l-lys-l-asn-gly-gly-l-pro-l-ser-l-ser-gly-l-ala-l-pro-l-pro-l-ser-l-lys-l-lys-l-lys-l-lys-l-lys-l-lys-nh2
| Molecular Weight | 4858 g/mol |
|---|---|
| Molecular Formula | C215H347N61O65S |
| XLogP3 | -30.8 |
| Hydrogen Bond Donor Count | 70 |
| Hydrogen Bond Acceptor Count | 77 |
| Rotatable Bond Count | 170 |
| Exact Mass | 4857.5510314 g/mol |
| Monoisotopic Mass | 4855.5443218 g/mol |
| Topological Polar Surface Area | 2090 Ų |
| Heavy Atom Count | 342 |
| Formal Charge | 0 |
| Complexity | 11800 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 42 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.
Treatment of type II diabetes mellitus
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
A10BJ03
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BJ - Glucagon-like peptide-1 (glp-1) analogues
A10BJ03 - Lixisenatide
Global Sales Information
ABOUT THIS PAGE
A Lixisenatidum manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lixisenatidum, including repackagers and relabelers. The FDA regulates Lixisenatidum manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lixisenatidum API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lixisenatidum supplier is an individual or a company that provides Lixisenatidum active pharmaceutical ingredient (API) or Lixisenatidum finished formulations upon request. The Lixisenatidum suppliers may include Lixisenatidum API manufacturers, exporters, distributors and traders.
Lixisenatidum Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lixisenatidum GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lixisenatidum GMP manufacturer or Lixisenatidum GMP API supplier for your needs.
A Lixisenatidum CoA (Certificate of Analysis) is a formal document that attests to Lixisenatidum's compliance with Lixisenatidum specifications and serves as a tool for batch-level quality control.
Lixisenatidum CoA mostly includes findings from lab analyses of a specific batch. For each Lixisenatidum CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lixisenatidum may be tested according to a variety of international standards, such as European Pharmacopoeia (Lixisenatidum EP), Lixisenatidum JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lixisenatidum USP).
LOOKING FOR A SUPPLIER?
